Patient-relevant outcomes from the phase III MARIPOSA-2 trial: amivantamab-chemotherapy versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer following disease progression on osimertinib
Tomasini, P. Juan-Vidal, O. Califano, R. Lin, C. C. Hulo, P. Dooms, C. Fang, J. Blasco, A. Kowalski, D. Salinas, J.
Tomasini, P.
Juan-Vidal, O.
Califano, R.
Lin, C. C.
Hulo, P.
Dooms, C.
Fang, J.
Blasco, A.
Kowalski, D.
Salinas, J.
Abstract
OBJECTIVE: The MARIPOSA-2 study demonstrated improved progression-free survival with amivantamab and chemotherapy compared with chemotherapy alone in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC) with disease progression on or after treatment with osimertinib. This publication describes the results of patient-reported outcomes (PROs) measures and time to symptomatic progression (TTSP) for 2 treatment arms. METHODS: PRO instruments included the European Organization for Research and Treatment of Cancer Quality of Life (QoL) Questionnaire Core 30 (EORTC QLQ-C30), Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8c, and the NSCLC Symptom Assessment Questionnaire. Changes from baseline were analyzed using mixed-effects models for repeated measures. Treatment comparisons were based on least-squares means. The hazard ratio for TTSP was estimated using a stratified Cox regression model with P value derived from a stratified log-rank test. RESULTS: Patients received amivantamab-chemotherapy (n = 131) or chemotherapy alone (n = 263). PRO scores were stable over time with little or no group differences in least-squares mean change from baseline. At 6 months postbaseline, 55.1% of patients in the amivantamab-chemotherapy arm reported improved or stable EORTC QLQ-C30 global health status/QoL scores compared with 29.1% in the chemotherapy arm. TTSP was prolonged for the amivantamab-chemotherapy treatment group versus chemotherapy alone (hazard ratio [HR] [95% CI], 0.73 [0.55-0.96]; nominal P = .0259). CONCLUSION: PRO results indicate that the clinical benefits of adding amivantamab to chemotherapy were achieved without compromising health-related QoL. Amivantamab-chemotherapy prolonged TTSP versus chemotherapy alone.
Authors
Tomasini, P.
Juan-Vidal, O.
Califano, R.
Lin, C. C.
Hulo, P.
Dooms, C.
Fang, J.
Blasco, A.
Kowalski, D.
Salinas, J.
Babu, G.
Mun, T. L.
Bearz, A.
Surmont, V.
Baldotto, C.
Sharma, R.
Arrieta, O.
Stencel, K.
Card, C.
Zer, A.
Massarelli, E.
Fang, B.
Mashru, S.
Schuchard, J.
Sermon, J.
Diels, J.
Chu, P. L.
Withelder, M.
Bauml, J. M.
Shah, S.
Baig, M.
Felip, E.
Juan-Vidal, O.
Califano, R.
Lin, C. C.
Hulo, P.
Dooms, C.
Fang, J.
Blasco, A.
Kowalski, D.
Salinas, J.
Babu, G.
Mun, T. L.
Bearz, A.
Surmont, V.
Baldotto, C.
Sharma, R.
Arrieta, O.
Stencel, K.
Card, C.
Zer, A.
Massarelli, E.
Fang, B.
Mashru, S.
Schuchard, J.
Sermon, J.
Diels, J.
Chu, P. L.
Withelder, M.
Bauml, J. M.
Shah, S.
Baig, M.
Felip, E.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Tomasini P, Juan-Vidal O, Califano R, Lin CC, Hulo P, Dooms C, et al. Patient-relevant outcomes from the phase III MARIPOSA-2 trial: amivantamab-chemotherapy versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer following disease progression on osimertinib. Clinical Lung Cancer. 2025 Dec 20;27(2):38-47. Epub 2026/01/17.